Zoetis Inc.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, MRK.DE has a market cap of 53.05B. Regarding current trading prices, ZOE.DE is priced at $135.20, while MRK.DE trades at $121.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas MRK.DE's P/E ratio is 18.95. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to MRK.DE's ROE of +0.10%. Regarding short-term risk, ZOE.DE is less volatile compared to MRK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, DMP.DE has a market cap of 2.12B. Regarding current trading prices, ZOE.DE is priced at $135.20, while DMP.DE trades at $39.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas DMP.DE's P/E ratio is 18.63. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to DMP.DE's ROE of +0.20%. Regarding short-term risk, ZOE.DE is more volatile compared to DMP.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, EVT.DE has a market cap of 1.25B. Regarding current trading prices, ZOE.DE is priced at $135.20, while EVT.DE trades at $7.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas EVT.DE's P/E ratio is -6.02. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to EVT.DE's ROE of -0.19%. Regarding short-term risk, ZOE.DE is less volatile compared to EVT.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, 2HQ.DE has a market cap of 369.26M. Regarding current trading prices, ZOE.DE is priced at $135.20, while 2HQ.DE trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas 2HQ.DE's P/E ratio is -0.38. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to 2HQ.DE's ROE of -0.29%. Regarding short-term risk, ZOE.DE is less volatile compared to 2HQ.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, PSG.DE has a market cap of 280.91M. Regarding current trading prices, ZOE.DE is priced at $135.20, while PSG.DE trades at $24.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas PSG.DE's P/E ratio is 15.54. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to PSG.DE's ROE of +0.49%. Regarding short-term risk, ZOE.DE is less volatile compared to PSG.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, HAEK.DE has a market cap of 111.50M. Regarding current trading prices, ZOE.DE is priced at $135.20, while HAEK.DE trades at $21.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas HAEK.DE's P/E ratio is 11.57. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to HAEK.DE's ROE of +0.06%. Regarding short-term risk, ZOE.DE is less volatile compared to HAEK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, 93M1.DE has a market cap of 103.18M. Regarding current trading prices, ZOE.DE is priced at $135.20, while 93M1.DE trades at $24.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas 93M1.DE's P/E ratio is 0.86. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to 93M1.DE's ROE of +0.41%. Regarding short-term risk, ZOE.DE is more volatile compared to 93M1.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, APPH.DE has a market cap of 91.21M. Regarding current trading prices, ZOE.DE is priced at $135.20, while APPH.DE trades at $10.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas APPH.DE's P/E ratio is 121.67. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to APPH.DE's ROE of +0.02%. Regarding short-term risk, ZOE.DE is more volatile compared to APPH.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, B8F.DE has a market cap of 20.67M. Regarding current trading prices, ZOE.DE is priced at $135.20, while B8F.DE trades at $6.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas B8F.DE's P/E ratio is -32.40. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to B8F.DE's ROE of +0.18%. Regarding short-term risk, ZOE.DE is less volatile compared to B8F.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, 21P1.F has a market cap of 19.64M. Regarding current trading prices, ZOE.DE is priced at $135.20, while 21P1.F trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas 21P1.F's P/E ratio is -0.01. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to 21P1.F's ROE of -0.06%. Regarding short-term risk, ZOE.DE is less volatile compared to 21P1.F. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, SBX.DE has a market cap of 18.59M. Regarding current trading prices, ZOE.DE is priced at $135.20, while SBX.DE trades at $3.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas SBX.DE's P/E ratio is -1.48. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to SBX.DE's ROE of -0.55%. Regarding short-term risk, ZOE.DE is less volatile compared to SBX.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, HOB0.F has a market cap of 17.00M. Regarding current trading prices, ZOE.DE is priced at $135.20, while HOB0.F trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas HOB0.F's P/E ratio is 6.30. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to HOB0.F's ROE of -1.18%. Regarding short-term risk, ZOE.DE is more volatile compared to HOB0.F. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, Z6A.F has a market cap of 4.52M. Regarding current trading prices, ZOE.DE is priced at $135.20, while Z6A.F trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas Z6A.F's P/E ratio is -0.02. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to Z6A.F's ROE of -0.23%. Regarding short-term risk, ZOE.DE is more volatile compared to Z6A.F. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, PA8.DE has a market cap of 2.71M. Regarding current trading prices, ZOE.DE is priced at $135.20, while PA8.DE trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas PA8.DE's P/E ratio is -0.13. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to PA8.DE's ROE of -0.09%. Regarding short-term risk, ZOE.DE is less volatile compared to PA8.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, 2NU.F has a market cap of 1.08M. Regarding current trading prices, ZOE.DE is priced at $135.20, while 2NU.F trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas 2NU.F's P/E ratio is -0.03. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to 2NU.F's ROE of N/A. Regarding short-term risk, ZOE.DE is less volatile compared to 2NU.F. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, ERV2.F has a market cap of 312475.00. Regarding current trading prices, ZOE.DE is priced at $135.20, while ERV2.F trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas ERV2.F's P/E ratio is -0.02. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to ERV2.F's ROE of +2.97%. Regarding short-term risk, ZOE.DE is more volatile compared to ERV2.F. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, 4XT.DE comparison data is unavailable. Regarding current trading prices, ZOE.DE is priced at $135.20, while 4XT.DE trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas 4XT.DE's P/E ratio is -2.18. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to 4XT.DE's ROE of -7.27%. Regarding short-term risk, ZOE.DE is more volatile compared to 4XT.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, MCD.DE comparison data is unavailable. Regarding current trading prices, ZOE.DE is priced at $135.20, while MCD.DE trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas MCD.DE's P/E ratio is -0.02. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to MCD.DE's ROE of -1.69%. Regarding short-term risk, ZOE.DE is less volatile compared to MCD.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.

ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZOE.DE stands at 60.31B. In comparison, BIO1.F comparison data is unavailable. Regarding current trading prices, ZOE.DE is priced at $135.20, while BIO1.F trades at $36.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZOE.DE currently has a P/E ratio of 27.48, whereas BIO1.F's P/E ratio is -22.85. In terms of profitability, ZOE.DE's ROE is +0.50%, compared to BIO1.F's ROE of +0.26%. Regarding short-term risk, ZOE.DE is more volatile compared to BIO1.F. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.